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Background: In humans, absorption and tissue retention rates of intramuscularly
administered hydroxocobalamin (OH-Cbl) are superior compared to cyanocobalamin
(CN-Cbl). Supplementation with OH-Cbl has not been described in cats.
Objectives: To evaluate effects of parenteral OH-Cbl supplementation on clinical signs,
serum Cbl and methylmalonic acid (MMA) concentrations in hypocobalaminemic cats
with gastrointestinal disease.
Animals: Twenty-three client-owned cats.
Methods: Prospective study. Serum Cbl and MMA concentrations were determined
at enrollment (t0), immediately before the 4th OH-Cbl IM injection (300 μg, given
q2 weeks) (t1), and 4 weeks after the 4th injection (t2). Severity of clinical signs
(activity, appetite, vomiting, diarrhea, body weight) was graded at each time point
and expressed as clinical disease activity score.
Results: Median clinical disease activity score decreased significantly from t0 (6;
range, 2-10) to t1 (1; range, 0-6) and t2 (1; range, 0-9). Median serum Cbl concentra-
tion increased significantly from 111 pmol/L (range, 111-218; reference range,
225-1451 pmol/L) at t0 to 1612 pmol/L (range, 526-14 756) (P < .001) at t1, and
decreased again significantly to 712 pmol/L (range, 205-4265) (P < .01) at t2. Median
baseline serum MMA concentration at t0 (802 nmol/L; range, 238-151 000; refer-
ence range, 120-420 nmol/L) decreased significantly (P < .001) to 199 nmol/L (range,
29-478) at t1, and was 205 nmol/L (range, 88-734) at t2. Serum MMA concentra-
tions normalized in 22/23 cats at t1, and were not significantly higher at t2 compared
to t1.
Conclusions and Clinical Importance: The herein described OH-Cbl injection scheme
appears efficacious for normalization of cellular Cbl deficiency in cats with gastroin-
testinal disease.
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1 | INTRODUCTION
Cobalamin (Cbl), also known as vitamin B12, is a water-soluble B-group
vitamin and an essential cofactor for nucleic acid synthesis and hema-
topoiesis. Naturally occurring forms of B12 are methyl-Cbl, adenosyl-
Cbl, and hydroxo-Cbl (OH-Cbl), whereas cyano-Cbl (CN-Cbl) is a syn-
thetic B12 compound commonly used in supplements.
1 Cbl absorption
requires binding proteins and specific receptors along various parts of
the gastrointestinal tract,1 and gastrointestinal disease can therefore
lead to Cbl deficiency. In cell metabolism, adenosyl-Cbl is needed as a
cofactor for the conversion of methylmalonyl-CoA to succinyl-CoA via
methylmalonyl-CoA mutase and for remethylation of homocysteine via
methionine synthase. In cats, Cbl deficiency causes a reduction in the
activity of methylmalonyl-CoA mutase, resulting in increases in serum
methylmalonic acid (MMA) concentrations, but cats do not have
increased homocysteine concentrations.2 Measurement of MMA
allows assessment of availability of Cbl for cells and is considered the
test of choice to detect cobalamin deficiency in people.3 Cats with
undetectable or subnormal Cbl concentrations also have significantly
increased MMA concentrations.4-7Although it is not yet known when
depletion of cellular Cbl stores and increases in MMA concentrations
begin in the course of subnormal serum Cbl concentrations, MMA is
currently considered the best indicator of Cbl status in cats.2,5-9
Administration of parenteral Cbl to cats with subnormal Cbl values is
currently considered a routine therapeutic procedure,5-8 especially
when daily oral Cbl supplementation is difficult to achieve.10 A widely
followed recommendation suggests to administer 250 μg Cbl once
weekly, for 6 weeks, followed by a dose 30 days later and determina-
tion of Cbl concentration 30 days after the last injection.11 At present,
CN-Cbl is generally recommended for routine usage in veterinary med-
icine, most probably because it is widely available and inexpensive.11 In
cats, only the use of CN-Cbl has been investigated so far,4,7,8 and it
was recently shown that a Cbl supplementation scheme consisting of
6 weekly IM (250 μg) injections of CN-Cbl failed to fully normalize
serum and urine MMA concentrations in hypocobalaminemic cats with
enteropathy.7 In people with various types of Cbl deficiencies, the
natural-occurring OH-Cbl is considered the mainstay treatment and
numerous studies consistently showed superior tissue retention rates
of Cbl after supplementation with OH-Cbl rather than CN-Cbl together
with increased urinary excretion of CN-Cbl.12-20 In addition, IM injec-
tions of OH-Cbl are thought to cause less pain than CN-Cbl in
people.15
For these reasons, we replaced CN-Cbl with OH-Cbl in our hospi-
tal in 2016 and this approach seemed to work well in our patients.
Based on clinical experience as well as sporadic assessments of Cbl
and MMA values, we decided to simplify our supplementation scheme
from 6 weekly IM (250 μg) injections to 4 IM (300 μg) injections given
every 2 weeks. The aim of the present study was therefore to evalu-
ate the efficacy of intramuscularly administered OH-Cbl on serum Cbl
and MMA concentrations in cats with hypocobalaminemia and gastro-
intestinal disease before and after IM injections of OH-Cbl given
every 2 weeks for a total of 4 doses. A secondary aim was to assess
the clinical benefits during OH-Cbl supplementation.
2 | MATERIALS AND METHODS
2.1 | Animals and study design
This study was conducted at the Clinic for Small Animal Internal Medi-
cine, Vetsuisse faculty, University of Zurich between September 2017
and November 2019. All cats were prospectively enrolled in the study
based on the following criteria: a history of clinical signs compatible
with gastrointestinal disease, which included diarrhea, vomiting, weight
loss, anorexia, or weight loss with polyphagia; a serum Cbl concentra-
tion below the reference interval (225-1451 pmol/L),22 and informed
owner consent. Concurrent hyperthyroidism at inclusion was not con-
sidered an exclusion criterion when the cats' serum thyroxine concen-
tration was within the reference range under treatment at enrollment
and cats also exhibited ultrasonographic evidence of intestinal disease
(generalized thickening of the muscularis layer of the small intestines)23
in addition to the abovementioned clinical signs.
All cats were supplemented with 4 IM injections of 300 μg OH-
Cbl (Vitarubin Depot, Streuli Pharma AG, 8730 Uznach, Switzerland)
given every 2 weeks (q2 weeks). Baseline serum samples were col-
lected before the first OH-Cbl injection (t0) and Cbl and MMA were
either measured directly at baseline, or serum aliquots were frozen at
−80C for later measurement of MMA concentration. Serum samples
were again collected immediately before the 4th OH-Cbl injection
(t1), and 4 weeks after the 4th OH-Cbl injection (t2) for measurement
of serum Cbl concentration. Aliquots for later analysis of serum MMA
concentration were directly frozen at −80C. All stored samples for
MMA measurements were shipped on dry ice to the laboratory, and
shipping time did not exceed 20 minutes.
To assess the clinical status of cats undergoing OH-Cbl supple-
mentation, anamnestic and clinical findings from time points t0-t1-t2
were summarized and expressed as a clinical disease activity score,
which ranged from 0 to 15. This score was based on the clinical signs
used in a feline chronic enteropathy activity index24 and included level
of activity, appetite, weight loss, vomiting, and diarrhea.7 The degree
of severity for each clinical sign was scored as normal (0 points), mild
(1 point), moderate (2 points), or severe (3 points). The study was
approved by the Cantonal Veterinary Office of Zurich and conducted
in accordance with guidelines established by the Animal Welfare Act
of Switzerland.
2.2 | Analyses
Serum Cbl concentration was measured with an automated competi-
tive binding chemiluminescence assay (Immulite 2000, vitamin B12,
Siemens Healthcare Diagnostics Inc, Newark, DE). The intra- and
interassay coefficients of variation (CV) of the Cbl assay were 2.1%
and 3.4%, respectively. The reference interval for serum Cbl was
225-1452 pmol/L.22 Cbl concentrations at inclusion <111 pmol/L
(below the detection limit) were truncated to 111 pmol/L for statistical
analysis. All serum MMA concentrations were analyzed in the Division
of Clinical Chemistry of the University Children's Hospital Zurich
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according to accredited methods. In brief, the samples were sup-
plemented with an internal standard, precipitated, and analysis was
done by ultraperformance liquid chromatography-tandem mass spec-
trometry (UPLC-TMS) on an Ultimate 3000 XRS UHPLC system
(Dionex; Thermo Scientific) with a SCIEX5500 mass spectrometer
(SCIEX, Framingham, Massachusetts) using multiple reaction moni-
toring. The lower limit of quantification for this method was
25 nmol/L. The interassay CV of the analyses were 5.8%. The refer-
ence intervals for serum MMA concentration was 120-420 nmol/L.7
2.3 | Statistical analysis
A Friedman-test followed by a Nemenyi post hoc test were conducted
to compare the effect of time on the repeated measures of serum Cbl,
and serum MMA values measured at the 3 time points t0, t1, and t2.
A Friedman-test followed by a Nemenyi post hoc test was also used
to assess changes over time in the clinical disease activity scores
(t0-t2). A Mann-Whitney test was used to compare MMA values at
baseline between polyphagic and nonpolyphagic cats. Statistical ana-
lyses and data visualization were done using statistical software
(R statistical program for analyses with PMCMR and lme4 library) and
graphing software (GraphPad Prism).
3 | RESULTS
3.1 | Animals
Breeds included European Shorthair (16/23), Balinese cat (1), British
Longhair (1), Devon Rex (1), Egyptian Mau (1), Maine Coon (1), Norwe-
gian forest cat (1), and Russian Blue (1). The median age was 12 years
(range, 5 months to 18 years), median body weight was 3.7 kg (range,
1.62-7.66), and median body condition score was 4 (2–5). Clinical signs
present at the time of enrollment into the study were lethargy (19/23),
weight loss (18/23), vomiting (15/23), small bowel diarrhea (15/23),
inappetence or anorexia (12/23), and polyphagia (10/23). All 10 cats
with subjectively increased appetite (polyphagia) had concurrent
weight loss.
3.2 | Clinicopathologic evaluation
After obtaining a clinical history, all cats underwent a physical examina-
tion and laboratory testing including a CBC, serum biochemistry panel,
and urinalysis. Two cats were hyperthyroid and received medical treat-
ment. Serum thyroxine concentration was measured in all 23 cats at
baseline evaluation, and was well within the reference range in all cats.
All cats were evaluated for pancreatitis using the DGGR-lipase assay25;
9/23 cats had increased values. Two cats had minimally increased lipase
activities (28, and 29 U/L; reference interval, 8-26 U/L), the other 7 cats
had a median value of 69 U/L (range, 43-292 U/L) which was considered
suggestive of pancreatitis.26 Serum trypsinogen-like immunoreactivity
(fTLI) was measured in 18 cats, and 1 cat was diagnosed with exocrine
pancreatic insufficiency based on a fTLI value of 0.1 μg/L. All cats had
been routinely dewormed (17/23) or had negative fecal analysis
results (6/23).
Abdominal ultrasonography carried out in all 23 cats at the time of
presentation showed abnormal intestinal findings in 22. Diffuse thick-
ening of the muscularis layer of the small intestines was seen in
20, mesenteric lymphadenopathy in 14, and generalized hyperechoicity
of the mucosal layer of the small intestines in 2 of the 23 cats. Histo-
logic examination of the intestines was available for 12 cats after col-
lection of endoscopic (gastroduodenoscopy and ileocoloscopy) biopsy
specimens (7), full-thickness biopsy specimens during surgery (4), or
both specimens during postmortem examination (2).
3.3 | Definitive and tentative diagnoses
A definitive (ie, histologic) diagnosis of gastrointestinal tract disease
was available in 16 of 23 cats and comprised intestinal small cell lym-
phoma (8), inflammatory enteropathy (4; all lymphoplasmacytic enteri-
tis), cholangitis/cholangiohepatitis (2; both cats also had suspected
chronic enteropathy based on a thickened lamina muscularis propria),
pancreatitis (1; well-documented intra vitam, and confirmed on later
postmortem examination together with lymphoplasmacytic enteritis
and lymphoplasmacytic cholangiohepatitis), and exocrine pancreatic
insufficiency (1). Chronic enteropathy was suspected in the 7
remaining cats based on clinical signs, low serum Cbl concentra-
tion, and compatible ultrasonographic features of the intestines,
but was not confirmed histologically. Concurrent hyperthyroidism
was known for 2 cats (1 with a clinical diagnosis of chronic enteropa-
thy, 1 with small cell lymphoma). One cat had concurrent stage
2 chronic kidney disease (serum creatinine, 180 μmol/L; reference
range, 98-163 μmol/L).
3.4 | Treatment
Treatments in addition to OH-Cbl supplementation varied among cats
and included dietary changes (17/23), prednisolone (15/23), pro-
biotics (9/23), chlorambucil (7/23), antibiotics (2/23), and transdermal
methimazole27 (2).
3.5 | Concentrations of serum Cbl, and
serum MMA
At baseline, 16/23 cats had undetectable serum Cbl concentrations
<111 pmol/L (reference range, 225-1452 pmol/L), and 7 cats had sub-
normal values (median 165 pmol/L; range, 135-218). Serum Cbl con-
centration (Figure 1) differed significantly over time (χ2 44.087,
P < .001). There was a significant increase (P < .001) in the median
serum Cbl concentration from 111 pmol/L (range, 111-218) at t0 to
1612 pmol/L (range, 526-14 756) at t1, followed by a significant
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(P < .01) decrease to 712 pmol/L, range, 205-4265) 4 weeks after the
end of supplementation (t2).
At baseline, 20/23 cats had serum MMA concentrations above the
reference range (120-420 nmol/L). The corresponding MMA and Cbl
values of the 3 cats with normal serum MMA concentrations were the
following: 238 nmol/L and <111 pmol/L, 336 nmol/L and 165 pmol/L,
and 403 nmol/L and 151 pmol/L).
Serum MMA concentration (Figure 2) also differed significantly
over time (χ2 34.615, P < .001). The post hoc analysis showed that the
median serum MMA concentration decreased significantly (P < .001)
from 802 nmol/L (range, 238-151 000) at t0 to 199 nmol/L (range,
29-478) at t1. All but 1 cat had serumMMA concentrations in the refer-
ence range at t1. Median MMA concentrations (205 nmol/L; range,
88-734) 4 weeks after the last Cbl injection (t2) did not differ signifi-
cantly from t1. Cats presenting with polyphagia and weight loss (n = 10)
had significantly (P = .04) higher median serum MMA concentrations
(1291 nmol/L) compared to 13 cats without polyphagia (670 nmol/L).
3.6 | Clinical signs
The clinical disease activity scores (Figure 3) differed significantly over
time (χ2 24.617, P < .001). The median clinical disease activity score
was 6 (range, 2-10) at t0 and decreased significantly (P < .001) to
1 (range, 0-6) at t1, and remained at 1 (range, 0-9) 4 weeks later (t2).
4 | DISCUSSION
In cats with Cbl deficiency and signs of gastrointestinal disease, 3 IM
injections of 300 μg OH-Cbl given every 2 weeks, significantly
increased serum Cbl concentrations to supranormal values at t1,
followed by a significant decrease to a median Cbl concentration
within the reference range 4 weeks after the 4th injection. The
median concentration of serum MMA decreased significantly into the
reference range at t1, and results 4 weeks later at t2 did not differ sig-
nificantly from t1. At t1, only 1/23 cats had a mildly increased serum
MMA concentration (478 nmol/L), and this cat (diagnosis SCL) also
had the highest serum MMA concentration (734 nmL/L) measured at
t2. The combination of reduced frequency of required injections and
F IGURE 1 Scatter plot for serum Cbl concentration at baseline
(t0), directly before the 4th IM injection of 300 μg OH-Cbl given
q2 weeks (t1), and 4 weeks after the 4th injection (t2); bars represent
median values. At t2, the asterisk denotes an outlier with
14 756 pmol/L
F IGURE 2 Scatter plot for serum MMA concentration at baseline
(t0), directly before the 4th IM injection of 300 μg OH-Cbl given
q2 weeks (t1), and 4 weeks after the 4th injection (t2); bars represent
median values. At t0, the asterisk denotes an outlier with
151 000 nmol/L
F IGURE 3 Scatter plot for the clinical disease activity score at
baseline (t0), directly before the 4th IM injection of 300 μg OH-Cbl
given q2 weeks (t1), and 4 weeks after the 4th injection (t2); bars
represent median values
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superior posttreatment MMA concentrations highlight the advantages
of OH-Cbl over CN-Cbl.
It has traditionally been recommended that serum Cbl concentra-
tion should be above the reference range at the time of retesting, and if
supranormal serum cobalamin concentrations have not been achieved
to continue supplementation every 2-4 weeks.11 Our data at t1 and t2
do not support a strict need for supranormal serum Cbl results at
retesting as MMA concentrations did not differ between both time
points, even though median serum Cbl concentration had decreased
again into the reference range. The results of the clinical disease activity
score (significant decrease from t0 to t1 and no further change at t2)
support this assumption, even if clinical signs must be interpreted with
caution as all cats had also received additional treatment.
To our knowledge, supplementation with OH-Cbl has not been
reported before in cats. In a previous study assessing a supplementa-
tion scheme with 6 weekly IM CN-Cbl injections in 20 cats with
chronic enteropathy, serum and urine MMA concentrations had not
fully normalized in 12/20 and 6/20 cats after 5 injections.7 Besides,
the median serum Cbl concentration after 6 weekly CN-Cbl injections
was lower (612 pmol/L) compared to 4 weeks after 4 OH-Cbl injec-
tions given q2 weeks in this study (712 pmol/L).7
Although varied concurrent treatments could have also influenced
our results, we presume these differences in outcome might relate to
the Cbl formulation. It has been shown experimentally in dogs that only
a minor part of the injected dose of CN-Cbl is eventually utilized,
whereas a large percentage is being lost in the urine during the first
hours after injection.18 When the same dogs received OH-Cbl, higher
serum binding and more prolonged increases in serum Cbl concentra-
tions and lower urinary excretion was noted compared with CN-Cbl.18
It was speculated that the difference in serum binding may lie in the
chemical stability of CN-Cbl, which limits the sites at which it may be
bound as compared to OH-Cbl which readily dissociated and may equil-
ibrate with a variety of serum constituents.17 Possible differences in
protein binding likely have also implications for cellular markers of Cbl
availability as only Cbl bound to transcobalamin is available to cells.30
Superior bioavailability of OH-Cbl over CN-Cbl has also been
proven in humans. Slower disappearance of OH-Cbl from site of injec-
tion, increased liver uptake, and less rapid urinary excretion when com-
pared with CN-Cbl were demonstrated by various authors.14,15-20,28
Hertz et al reported that after IM injection of 1 mg CN-Cbl and
OH-Cbl, healthy individuals excreted within 24 hours about 80% and
about 25%, respectively, in the urine.15 Further dialysis experiments
showed that OH-Cbl passed more slowly through membranes than
does CN-Cbl, and that OH-Cbl is bound to serum proteins in far greater
quantities than is CN-Cbl.15 These observations were confirmed in
long-term studies when humans with pernicious anemia were given
equal amounts of either OH-Cbl or CN-Cbl IM injections,14,17 and simi-
lar results have been published when comparing oral OH-Cbl to CN-
Cbl.29 Against this background, it is interesting to note that it has also
been mentioned in small animal medicine that CN-Cbl might fail to
increase serum Cbl concentrations for reasons currently not under-
stood, and it has been speculated that OH-Cbl might instead be more
effective in these patients.11
Superior bioavailability of OH-Cbl in humans may be because of
different affinities for the blood-transport binding proteins, cell recep-
tors for Cbl uptake, and intracellular enzymes involved in their conver-
sion to intracellular cobalamin.13 The latter could have been the
reason that CN-Cbl injections in humans with an inherited disorder of
intracellular Cbl metabolism were inadequate, and biochemical (ie,
MMA, homocysteine) as well as clinical parameters normalized only
after patients were switched to OH-Cbl injections.21 Unfortunately,
very little is known about Cbl-binding proteins in cats,31 and studies
on cellular uptake and activation of intracellular methylmalonyl-CoA
mutase have not been carried out. Our serum MMA results at t1 and
t2 basically agree with the concept of improved cellular uptake of
OH-Cbl when comparing it to MMA results after supplementation
with CN-Cbl.7 However, differences in the study designs hinder direct
comparisons of results. Instead of 6 weekly injections, 4 injections
given q2 weeks were administered in the present study and also the
dosage per IM injection was increased from 250 to 300 μg. The nor-
malized postsupplementation Cbl and MMA values in our study
(t1) therefore reflect the effects of 3 OH-Cbl 300 μg injections,
whereas the results of the follow-up measurement reflect the effect
of 4 OH-Cbl 300 μg injections. The rationale behind this simplified
approach was to facilitate the whole Cbl supplementation process for
our patients. Our previous clinical experience with OH-Cbl in cats let
us to believe that cats would similar to humans also have better bio-
availability of OH-Cbl. A positive side-effect of the shortened supple-
mentation was that we could spare our patients hospital visits which
improved overall compliance. It had taken 4 years to include 20 cats
for our previous study,7 and almost all of the participating cat owners
described the supplementation protocol of 6 weekly injections and
additional rechecks as cumbersome.
Cats displaying a combination of polyphagia and weight loss had sig-
nificantly higher serum MMA concentrations compared to cats without
polyphagia. This comparison could not be made for serum Cbl as almost
all results were <111 pmol/L. Polyphagia with concurrent weight loss is a
hallmark clinical sign of malabsorption and usually regarded as an indica-
tor of clinical disease severity. In the future, MMA might be a biomarker
for disease severity in cats with gastrointestinal disease, however at least
at this point the cost of analysis complicates routine use.
Our study had several limitations. One limitation was the inclu-
sion of cats with more than 1 clearly defined disease process as well
as with different stages and severity of disease. However, we believe
this was unavoidable. Even if only cats with 1 diagnosis (eg, intestinal
SCL) had been included, it would have been impossible to guarantee
uniform spatial distribution of disease among patients. That means we
could not control for individual interference with renewed absorption
of biliary Cbl during enterohepatic circulation. Another limitation was
that our modified injection scheme made direct comparisons of OH-
Cbl versus CN-Cbl supplementation difficult. Furthermore, concurrent
individual treatments made it difficult to accurately assess the magni-
tude of the beneficial clinical effect of OH-Cbl supplementation, but
we could not justify withholding necessary medical treatments. The
magnitude of remission of clinical signs at t1 (1; range, 0-6) was the
same compared to the identical score used in the previous study with
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CN-Cbl,7 but also in the previous study most cats received additional
treatments.
In conclusion, our findings show that 4 injections of OH-Cbl are
efficacious for normalization of serum Cbl and cellular Cbl deficiency
in cats with hypocobalaminemia and gastrointestinal disease. The ben-
eficial metabolic effects appear to be greater when compared to pre-
viously published results with CN-Cbl.7 Comparative studies on the
optimal Cbl formulation (OH-Cbl versus CN-Cbl) are needed in cats
with Cbl deficiency.
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